JPRN-UMIN000002343招募中2 期
Randomized phase II clinical study on preventive effects of GPS, healthy food on the incidence of infection cases in stomach and colon cancer patients before and after the abdominal surgery - Preventive effects of GPS on the incidence of infection cases in cancer patients before and after surgery
Research institute of cancer chemotherapy0 个研究点目标入组 200 人开始时间: 2009年8月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Sevier compromised patient(more than PS3) 2.Patient of SHOWKAKAN KYOUSAKU or breading 3.SHINKOUSEI infectious patient 4.Urgent operation patient 5.ZOUKIFUZEN patient 6.Uncontrollable patients together with diabetes mellitus and treated with insulin 7.Suspected cases allergic to yeasts 8.Patient who has been treated with chemotherapy 9.Other patients who are considered to be ruled out by the doctor concerned
研究者
相似试验
招募中
2 期
High humidity decreases symptomatic patent ductus arteriosusJPRN-jRCT1032190068Hirata Michisato30
已完成
2 期
Phase II study of the effectiveness of prophylaxis against side effects associated with Afatinib (NLCTG 1401)non-small cell lung cancerJPRN-UMIN000016167iigata Lung Cancer Treatment Group30
进行中（未招募）
1 期
Study of Efficacy of REVTx-99 against Influenza infection.Influenza AEUCTR2021-003463-97-BERevelation Biosciences, Inc.60
已完成
1 期
A phase I/II clinical trial of prophylactic extended-field radiotherapy of pelvic and para-aortic lymph nodes in locally advanced squamous cell carcinoma of the uterine cervix using carbon-ion beamsuterine cervical cancerJPRN-UMIN000016169ational Institute of Radiological Sciences20
进行中（未招募）
1 期
Randomized Phase II study for evaluation of efficacy and safety of maintenance treatment with 5-FU/FA plus panitumumab vs. 5-FU/FA alone after prior induction treatment with mFOLFOX6 plus panitumumab and re-induction with mFOLFOX6 plus panitumumab in case of progression for first-line treatment of patients with metastatic colorectal cancerEUCTR2012-005422-30-DEAIO Studien gGmbH400